184 related articles for article (PubMed ID: 10763396)
21. Estimating the Cost of Illness of Prostate Cancer in Iran.
Mojahedian MM; Toroski M; Keshavarz K; Aghili M; Zeyghami S; Nikfar S
Clin Ther; 2019 Jan; 41(1):50-58. PubMed ID: 30545740
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts.
Amankwah N; Marrie RA; Bancej C; Garner R; Manuel DG; Wall R; Finès P; Bernier J; Tu K; Reimer K
Health Promot Chronic Dis Prev Can; 2017 Feb; 37(2):37-48. PubMed ID: 28273039
[TBL] [Abstract][Full Text] [Related]
23. The burden of depression in prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
[TBL] [Abstract][Full Text] [Related]
24. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
25. Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis.
Pearce AM; Ryan F; Drummond FJ; Thomas AA; Timmons A; Sharp L
Support Care Cancer; 2016 Feb; 24(2):879-886. PubMed ID: 26245495
[TBL] [Abstract][Full Text] [Related]
26. [The human and economic burden of cancer in France in 2014, based on the Sniiram national database].
Tuppin P; Pestel L; Samson S; Cuerq A; Rivière S; Tala S; Denis P; Drouin J; Gissot C; Gastaldi-Ménager C; Fagot-Campagna A
Bull Cancer; 2017 Jun; 104(6):524-537. PubMed ID: 28285755
[TBL] [Abstract][Full Text] [Related]
27. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
28. The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies.
Borre M; Nerstrøm B; Overgaard J
Acta Oncol; 1997; 36(7):681-7. PubMed ID: 9490083
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
30. The projected economic and health burden of sub-optimal asthma control in Canada.
Zafari Z; Sadatsafavi M; Chen W; FitzGerald JM
Respir Med; 2018 May; 138():7-12. PubMed ID: 29724396
[TBL] [Abstract][Full Text] [Related]
31. Estimates of the lifetime costs of breast cancer treatment in Canada.
Will BP; Berthelot JM; Le Petit C; Tomiak EM; Verma S; Evans WK
Eur J Cancer; 2000 Apr; 36(6):724-35. PubMed ID: 10762744
[TBL] [Abstract][Full Text] [Related]
32. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
[TBL] [Abstract][Full Text] [Related]
33. The economic burden of traumatic spinal cord injury in Canada.
Krueger H; Noonan VK; Trenaman LM; Joshi P; Rivers CS
Chronic Dis Inj Can; 2013 Jun; 33(3):113-22. PubMed ID: 23735450
[TBL] [Abstract][Full Text] [Related]
34. The economic impact of overactive bladder syndrome in six Western countries.
Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
[TBL] [Abstract][Full Text] [Related]
35. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
36. Phase-specific and lifetime costs of cancer care in Ontario, Canada.
de Oliveira C; Pataky R; Bremner KE; Rangrej J; Chan KK; Cheung WY; Hoch JS; Peacock S; Krahn MD
BMC Cancer; 2016 Oct; 16(1):809. PubMed ID: 27756310
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer--prevalence-based healthcare costs.
Norlund A; Alvegård T; Lithman T; Merlo J; Noreen D
Scand J Urol Nephrol; 2003; 37(5):371-5. PubMed ID: 14594683
[TBL] [Abstract][Full Text] [Related]
38. The cost of schizophrenia: lessons from an international comparison.
Blomqvist AG; Léger PT; Hoch JS
J Ment Health Policy Econ; 2006 Dec; 9(4):177-83. PubMed ID: 17200594
[TBL] [Abstract][Full Text] [Related]
39. Economic burden of cancer across the European Union: a population-based cost analysis.
Luengo-Fernandez R; Leal J; Gray A; Sullivan R
Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
[TBL] [Abstract][Full Text] [Related]
40. Cost of illness of the prostate cancer in Japan--a time-trend analysis and future projections.
Kitazawa T; Matsumoto K; Fujita S; Seto K; Hanaoka S; Hasegawa T
BMC Health Serv Res; 2015 Oct; 15():453. PubMed ID: 26438194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
